Start here if you're new
what it is
Revvity sells the tests, lab tools, and services that hospitals and researchers use to find disease and run experiments.
how it gets paid
Last year Revvity made $2.9B in revenue. Diagnostics instruments and assays was the main engine at $1.08B, or 37% of sales.
why it's growing
Revenue grew 3.7% last year. Revenue was $2.1 billion, up 198% vs. prior year, while full-year EPS reached $5.00 versus $4.90 in 2024.
what just happened
Last quarter, Revvity posted $1.70 in EPS versus a $1.63 estimate, a 4.29% beat.
At a glance
B++ balance sheet — above average — nothing keeping you up at night
50/100 earnings predictability — expect surprises
22.9x trailing p/e — priced about right
0.2% dividend yield — cash in your pocket every quarter
8.5% return on capital — nothing to write home about
xvary composite: 59/100 — below average
What they do
Revvity sells the tests, lab tools, and services that hospitals and researchers use to find disease and run experiments.
Revvity wins by sitting inside your lab routine. Switching costs (rewriting validated tests and retraining staff) → changing vendors is painful → customers tend to stay. That matters because Diagnostics was 54% of 2024 sales and Life Sciences was 46%, giving Revvity a $2.9 billion base spread across labs that do not enjoy operational drama.
How they make money
$2.9B
annual revenue · their business grew +3.7% last year
Diagnostics instruments and assays
$1.08B
Diagnostics services and software
$0.49B
Life Sciences instruments
$0.80B
Life Sciences reagents and consumables
$0.33B
Lab services and other
$0.20B
The products that matter
lab tools and diagnostics
Life Sciences Tools & Diagnostics
$2.9B revenue · 100% of sales shown here
this is the whole business in the snapshot data. it produced $2.9B of revenue with a 20.2% net profit margin, so profitability is clear even if the internal mix is not.
entire business
Key numbers
$4.0B
2029 sales
That is the 2029 revenue estimate, up from $2.9 billion today. Your bull case needs roughly $1.1 billion of added sales.
22.9x
trailing p/e
That multiple says you are not buying a busted stock. You are buying a recovery story that already has expectations attached.
8.5%
return on capital
Return on capital (profit earned on money invested in the business) → 8.5% → the company is productive, but not a machine.
12.5%
operating margin
Operating margin (profit after running the business, before interest and taxes) → 12.5% → there is room for improvement, but not much room for mistakes.
Financial health
B++
strength
- balance sheet grade B++ — above average financial health
- risk rank 3 — safer than 50% of stocks
- price stability 55 / 100
- long-term debt $2.6B (17% of capital)
- net profit margin 24.3% — keeps 24 cents of every dollar in revenue
- return on equity 10% — $0.10 profit for every $1 investors have put in
B++ — functional but not a standout on the balance sheet.
Total return vs. market
You invested $10,000 in RVTY 3 years ago → it's now worth $8,570.
The index would have given you $14,770.
source: institutional data · total return
What just happened
beat estimates
Last quarter, Revvity posted $1.70 in EPS versus a $1.63 estimate, a 4.29% beat.
Revenue was $2.1 billion, up 198% vs. prior year, while full-year EPS reached $5.00 versus $4.90 in 2024. The beat was real, but the bigger question is whether it starts a durable growth stretch.
$2.1B
revenue
$1.70
eps
4.29%
eps surprise
the number that mattered
The 4.29% EPS beat mattered most because the stock already ran 18%, so Revvity now has to keep beating, not just meet estimates.
-
meanwhile, the company has been active on the acquisition front.in november, revvity inked a definitive agreement to acquire acd/labs, a global provider of scientific software solutions that support analytical characterizations and molecular design across pharmaceutical and material sciences end markets.
-
the transaction is slated to close in early 2026.
-
the investment community seems to have renewed interest in revvity stock.
-
to wit, the issue has jumped approximately 18% in value since our early november review.by way of comparison, the s&p 500 index posted a relatively flat performance over the same time frame.
-
the company is in sound financial shape.revvity ended the september interim with $931.4 million in cash on its ledger (down $298.4 million since this time last year), and long-term debt of $2.631 billion (versus $3.186 billion 12 months ago).
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is slow growth meeting a quality-stock valuation.
med
the business stays fine and the stock still goes nowhere
revenue grew 3.7% last year. that works for a defensive operator. it works less well when the stock trades at 22.9x trailing earnings and has trailed the market by $6,200 on a $10,000 starting point over three years.
if growth stays stuck around 3–4%, the multiple has to do most of the work. that's a fragile setup.
med
acd/labs adds complexity before it adds proof
the early-2026 close gives Revvity a software angle, but this snapshot does not give you evidence yet that the deal lifts growth or margins. management gets another integration job while the core business is still moving at a modest pace.
if the deal closes and EPS still struggles to get past the $5.25 estimate, investors may see motion instead of value creation.
med
profitability is good, but the reinvestment engine is only average
a 20.2% net margin gives Revvity room to absorb friction. a 6.5% return on capital says that room is not endless. in plain English: this business earns money well, but it has not shown elite skill at turning each extra dollar into outsized future profit.
small misses matter more when capital efficiency is already modest.
at $2.9B of revenue growing 3.7%, these risks do not need to break the business to hurt the stock. they only need to keep Revvity looking ordinary at 22.9x earnings.
source: institutional data · regulatory filings · risk analysis
Pay attention to
earnings
the next quarter needs more than another stable print
if revenue growth stays near the current 3.7% annual pace and margin stays near 8.4%, the stock is still paying up for a business that has not sped up.
growth
can Revvity get clearly above 4%
that is the cleanest line in the story. below that, you own a steady operator. above that, the rerating case starts to earn its keep.
acd/labs
integration needs to show up in numbers, not slide decks
after the expected early 2026 close, the key question is simple: does earnings power move beyond the current $5.25 expectation.
capital efficiency
return on capital is still only 6.5%
if that number stays weak, the business keeps looking profitable but average at turning reinvestment into value.
Analyst rankings
short-term outlook
average
momentum score 3 — in human-speak, analysts think the stock is acting normal, not special.
risk profile
average
stability score 3 — you are not buying a bunker stock, but you are not buying a chaos machine either.
chart momentum
below average
technical score 4 — the chart still looks weaker than the recent share move might imply.
earnings predictability
50 / 100
earnings predictability means how often estimates stay on script. at 50 / 100, this one can surprise you — and surprises matter more at 22.9x earnings.
source: institutional data
Institutional activity
217 buyers vs. 276 sellers in 3q2025. total institutional holdings: 0.1B shares.
source: institutional data
Price targets
3-5 year target range
$88
$169
$115
current price
$129
target midpoint · +12% from current · 3-5yr high: $185 (+60% · 13% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive